{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:40:57Z","timestamp":1792734057053,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116191","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T22:08:33Z","timestamp":1712354913000},"page":"116191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["CYP2C9, CYP3A and CYP2C19 metabolize \u03949-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1)"],"prefix":"10.1016","volume":"228","author":[{"given":"King Clyde B.","family":"Yabut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Winnie Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiann T.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Isoherranen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116191_b0005","unstructured":"Centers for Disease Control and Prevention, Data and Statistics, (2022). https:\/\/www.cdc.gov\/marijuana\/data-statistics.htm (accessed January 15, 2024)."},{"key":"10.1016\/j.bcp.2024.116191_b0010","unstructured":"National Institute on Drug Abuse (NIDA), Marijuana and hallucinogen use among young adults reached all time-high in 2021 | National Institute on Drug Abuse (NIDA), (2022). https:\/\/nida.nih.gov\/news-events\/news-releases\/2022\/08\/marijuana-and-hallucinogen-use-among-young-adults-reached-all-time-high-in-2021 (accessed January 10, 2024)."},{"key":"10.1016\/j.bcp.2024.116191_b0015","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.lfs.2006.12.032","article-title":"Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes","volume":"80","author":"Watanabe","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116191_b0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03602532.2015.1137307","article-title":"Metabolomics of \u0394-9-tetrahydrocannabinol: implications in toxicity","volume":"48","author":"Dinis-Oliveira","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2024.116191_b0025","first-page":"21","article-title":"Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man","volume":"38","author":"Agurell","year":"1986","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2024.116191_b0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/can.2019.0037","article-title":"Human pharmacokinetic parameters of orally administered \u03949-tetrahydrocannabinol capsules are altered by fed versus fasted conditions and sex differences","volume":"4","author":"Lunn","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.bcp.2024.116191_b0035","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jps.20037","article-title":"Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans","volume":"93","author":"Naef","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116191_b0040","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1172\/JCI107431","article-title":"Comparative Pharmacology of A-Tetrahydrocannabinol and its Metabolite, 11-OH-\u03949-Tetrahydrocannabinol","author":"Lemberger","year":"1973","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2024.116191_b0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.170.3964.1320","article-title":"Marihuana: Studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man","volume":"170","author":"Lemberger","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116191_b0050","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1248\/bpb.18.1138","article-title":"Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman","volume":"18","author":"Watanabe","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2024.116191_b0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/dmd.118.085548","article-title":"Hepatic enzymes relevant to the disposition of (\u2212)-\u03949-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0060","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","article-title":"CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin","volume":"70","author":"Bland","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116191_b0065","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.119.086470","article-title":"Quantifying hepatic enzyme kinetics of (-)-\u03949-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0070","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1021\/acsmedchemlett.3c00017","article-title":"Cytosolic enzymes generate cannabinoid metabolites 7-carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol","volume":"14","author":"Beers","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2024.116191_b0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.2008.213","article-title":"Interindividual variation in the pharmacokinetics of \u03949-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9","volume":"85","author":"Sachse-Seeboth","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116191_b0080","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1124\/dmd.108.020396","article-title":"Differential genotype dependent inhibition of CYP2C9 in humans","volume":"36","author":"Kumar","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2024.116191_b0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/2193-1801-2-236","article-title":"A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of THC\/CBD Oromucosal Spray in Healthy Volunteers","volume":"2","author":"Stott","year":"2013","journal-title":"SpringerPlus"},{"key":"10.1016\/j.bcp.2024.116191_b0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1248\/bpb1978.7.254","article-title":"Difference in epoxides formation and their further metabolism between \u0394-9 and \u0394-8 tetrahydrocannabinols by human liver microsomes","volume":"7","author":"Yamamoto","year":"1984","journal-title":"J. Pharmacobiodyn."},{"key":"10.1016\/j.bcp.2024.116191_b0095","first-page":"241","article-title":"Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol","volume":"20","author":"Bornheim","year":"1992","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00414-017-1692-5","article-title":"8\u03b2-OH-THC and 8\u03b2,11-diOH-THC\u2014minor metabolites with major informative value?","volume":"132","author":"Gasse","year":"2018","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.bcp.2024.116191_b0105","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1089\/can.2021.0068","article-title":"Objective identification of cannabis use levels in clinical populations is critical for detecting pharmacological outcomes","volume":"7","author":"Huang","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.bcp.2024.116191_b0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-008-1260-2","article-title":"Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC","volume":"201","author":"Hunault","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2024.116191_b0115","first-page":"624","article-title":"Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency","volume":"255","author":"Thomas","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116191_b0120","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/tx500203s","article-title":"Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity","volume":"27","author":"Kandel","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bcp.2024.116191_b0125","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.lfs.2004.03.032","article-title":"The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes","volume":"75","author":"Zhou","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116191_b0130","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.107.019885","article-title":"The \u201calbumin effect\u201d and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0135","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1124\/dmd.122.001010","article-title":"Impact of intracellular lipid binding proteins on endogenous and xenobiotic ligand metabolism and disposition","volume":"51","author":"Yabut","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.nutr.27.061406.093710","article-title":"The emerging functions and mechanisms of mammalian fatty acid-binding proteins","volume":"28","author":"Storch","year":"2008","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bcp.2024.116191_b0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11745-016-4155-8","article-title":"Fatty acid binding protein-1 (FABP1) and the human FABP1 T94A variant: Roles in the endocannabinoid system and Dyslipidemias","volume":"51","author":"Schroeder","year":"2016","journal-title":"Lipids"},{"key":"10.1016\/j.bcp.2024.116191_b0150","article-title":"Drugs Form Ternary Complexes with Human Liver Fatty Acid Binding Protein (FABP1) and FABP1 Binding Alters","volume":"5","author":"Yabut","year":"2024","journal-title":"Drug Metabolism, Mol Pharmacol"},{"key":"10.1016\/j.bcp.2024.116191_b0155","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1038\/s41598-019-44108-3","article-title":"FABP1 controls hepatic transport and biotransformation of \u03949-THC","volume":"9","author":"Elmes","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116191_b0160","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1021\/acs.biochem.8b00744","article-title":"Structural and functional interaction of \u03949-tetrahydrocannabinol with liver fatty acid binding protein (FABP1)","volume":"57","author":"Huang","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2024.116191_b0165","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/cid\/cix1116","article-title":"Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy-treated human immunodeficiency virus-infected individuals","volume":"66","author":"Manuzak","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2024.116191_b0170","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1124\/dmd.113.052639","article-title":"Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: Implications for risk assessment of multiple time-dependent inhibitor systems","volume":"41","author":"Lutz","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0175","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2125.1997.00601.x","article-title":"Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation","volume":"44","author":"Schmider","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116191_b0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J. Anesthesiol."},{"key":"10.1016\/j.bcp.2024.116191_b0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/dmd.108.023358","article-title":"Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (\u00b1)-Suprofen: A comparison of kinetics and probe substrate selection","volume":"37","author":"Hutzler","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0190","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1124\/dmd.112.045302","article-title":"Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-Benzyl-Nirvanol and (\u2212)-N-3-Benzyl-Phenobarbital: New potent and selective in vitro inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/dmd.120.090696","article-title":"Human liver microsomes immobilized on magnetizable beads: A novel approach to study in vitro drug metabolism","volume":"48","author":"Horspool","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2024.116191_b0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jinorgbio.2018.03.016","article-title":"Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2","volume":"184","author":"Arnold","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2024.116191_b0215","first-page":"228","article-title":"Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: A possible member of the cytochrome P-450IIC subfamily","volume":"40","author":"Bornheim","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116191_b0220","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1021\/ja00777a048","article-title":"Metabolism of (-)-\u03949- and (-)-\u03948-tetrahydrocannabinol by monkey liver","volume":"94","author":"Gurny","year":"1972","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2024.116191_b0225","first-page":"35","article-title":"Tolerance and disposition of tetrahydrocannabinol in man","volume":"215","author":"Hunt","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116191_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0379-0738(01)00538-2","article-title":"\u03949-THC, 11-OH-\u03949-THC and \u03949-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people","volume":"123","author":"Giroud","year":"2001","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.bcp.2024.116191_b0235","doi-asserted-by":"crossref","unstructured":"M.A. Huestis, Pharmacokinetics and Metabolism ofthe Plant Cannabinoids, \u03949-Tetrahydrocannabinol, Cannabidiol and Cannabinol, Handbook of Experimental Pharmacology (2005) 657\u2013690.","DOI":"10.1007\/3-540-26573-2_23"},{"key":"10.1016\/j.bcp.2024.116191_b0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.177.4043.62","article-title":"11-Hydroxy-\u03949-tetrahydrocannabinol: Pharmacology, disposition, and metabolism of a major metabolite of marihuana in man","volume":"177","author":"Lemberger","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116191_b0245","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1124\/dmd.122.000868","article-title":"Characterizing and quantifying extrahepatic metabolism of (\u2212)-\u03949-Tetrahydrocannabinol (THC) and its psychoactive metabolite, (\u00b1)-11-Hydroxy-\u03949-THC (11-OH-THC)","volume":"50","author":"Kumar","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2024.116191_b0250","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/pmic.201500433","article-title":"Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM\/SRM and HR-MRM\/PRM","volume":"16","author":"Nakamura","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.bcp.2024.116191_b0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11010-011-0847-9","article-title":"Acyl-CoA binding proteins interact with the acyl-CoA binding domain of mitochondrial carnitine palmitoyl transferase I","volume":"355","author":"Hostetler","year":"2011","journal-title":"Mol. Cell Biochem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:16:07Z","timestamp":1731474967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":50,"alternative-id":["S0006295224001746"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116191","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C9, CYP3A and CYP2C19 metabolize \u03949-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1)","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116191"}}